14th December 2017
Unichem Laboratories Limited (“Unichem”) has completed the sale and transfer of its domestic formulations business in India and Nepal, on a going concern basis by way of slump sale, to Torrent Pharmaceuticals Limited (TPL).
Going ahead Unichem will:
· focus attention on all aspects of the international business including finished formulations, API, contract manufacturing and contract research;
· increase its investments in R&D in the New Chemical and Biological Entities (NCE & NBE), Bio-similars and complex generics; and
· reward shareholders
Mr. Jayendra Shah, played a pivotal role in successful consummation of the transaction. He was the sole financial advisor to Unichem on negotiations, valuations and deal closure. N A Shah Associates LLP, Chartered Accountants were the advisors for tax and related matters and Trans Continental Capital Advisors Pvt. Ltd. were the strategic advisors.
About Unichem Laboratories Limited
Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. The Company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at www.unichemlabs.com